Notice of Results

Ergomed plc
01 September 2023
 

 

PRESS RELEASE

 

 

Notice of Interim Results

 

Guildford, UK - 31 August 2023: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2023 on 26 September 2023.

Members of the Company's Executive Management team including Dr Miroslav Reljanović (Executive Chairman), Jonathan Curtain (Chief Financial Officer) and Keith Byrne (SVP, Capital Markets & Strategy) will host an in-person briefing for analysts at 11.00 am BST on the day of the results at the offices of Numis, at 45 Gresham Street, London, EC2V 7BF. There will also be a live webcast and conference call with a Q&A session. The webcast will be shared on the Investor Portal section of the Company's website at www.ergomedplc.com.

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice President, Capital Markets and Strategy)




Numis (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown / Jack McLaren


 

Peel Hunt (Joint Broker)

James Steel / Dr Christopher Golden                                 

 

 

Tel: +44 (0) 20 7418 8900

 



Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

ergomed@consilium-comms.com





 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings